Stock Movers: Merck, USA Rare Earth, and Nvidia's AI Investments

Revolution Medicines Deal Falls Through

• 📉 Revolution Medicines saw a nearly 22% drop as Merck ended acquisition talks due to disagreements on price.
• 💰 A potential deal could have valued Revolution Medicines at approximately $30 billion.
• ⚠️ Talks may restart, or another buyer could emerge, as Merck seeks to strengthen its treatment portfolio.

USA Rare Earth Secures Government Funding

• 📈 USA Rare Earth shares surged over 22% after signing a non-binding letter of intent with the US Department of Commerce.
• 🤝 The company will receive $1.6 billion in funding to accelerate domestic rare earth element production, with the government taking a 10.1% stake.
• private investment of $1 billion to further boost heavy rare-earth production.
• 💡 This move aligns with efforts to reduce reliance on China for critical rare earth elements.

Nvidia Boosts CoreWeave's AI Capacity

• 🚀 Nvidia is investing an additional $2 billion in CoreWeave, a major AI chip maker.
• ⚡ This investment aims to accelerate the expansion of 5 gigawatts of AI computing capacity by 2030.
• 💻 CoreWeave will be among the first to deploy new Nvidia products, including storage systems and CPUs.
• 🤝 Nvidia will also assist CoreWeave with data center infrastructure and market its AI software to cloud partners.
• 📈 Coreweave's IPO shareholders have seen significant returns since its March 2025 offering.